Mood Disorders

Experts discuss why early treatment and tailored combos can curb bipolar disorder.

Learn more about ADHD and its intersection with the emerging DMDD space.

Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.

AI romance chatbots turn loneliness into attachment—explore why they feel so real, and mental health risks unfolding now.

See why ketamine boosts outcomes for treatment‑resistant depression.

Unpack hikikomori’s global rise—and what it reveals about psychiatry’s diagnostic limits.

New evidence suggests age-adjusted eGFR cutoffs refine CKD risk, guiding safer lithium use and avoiding unnecessary kidney alarms.

GLP-1 weight-loss drugs interact with eating disorder risks; experts urge careful screening and conversation.

Experts unpack child psychiatric medication: safety, early intervention, suicide risk, and managing side effects.

Study shows brief interpersonal therapy during pregnancy cuts depression through year postpartum.

Weight bias can obscure eating disorders in all body sizes; learn why early screening, asking questions, and trauma care change outcomes.

A consensus statement proposes a psychocardio response team to relieve the burden of comorbid cardiovascular and mental disease.

FDA feedback for CYC-126: anesthetic therapy with live EEG guidance aims to deliver precise relief for treatment-resistant depression.

How social media algorithms push violent clips, fueling desensitization, irritability, and compulsive scrolling—plus practical screening and treatment tips for clinicians.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Explore the unique mood-stabilizing properties of antiepileptics like lamotrigine, valproic acid, and carbamazepine in bipolar disorder treatment.

Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.

Explore the intersection of psychotherapy and pharmacology in treating mood disorders, emphasizing personalized approaches for optimal patient outcomes.

Tina Matthews-Hayes, DNP, CRNP, FNP-BC, discusses the importance of a therapeutic alliance with her patient with bipolar disorder.

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

In clinical practice, there are individuals who have chronic low-grade hypomanic symptoms: high energy, need for less sleep than others, chronic optimism, and chronic risk-taking.

Chatbots engage youth with connection but pose serious risks, potentially harming mental health and fostering unhealthy attachments. Awareness and regulation are crucial.

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Explore the complex interplay of genetics, environment, concussion, substance abuse, and inflammation in severe mental illnesses, revealing critical insights for prevention and treatment.

OpenAI acknowledges ChatGPT's risks to psychiatric patients and commits to improving safety measures, but skepticism about their sincerity remains.